ACUR - Acura Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Acura Pharmaceuticals, Inc.

616 N. North Court
Suite 120
Palatine, IL 60067
United States

IndustryDrug Delivery
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert B. JonesCEO, Pres & Director273kN/A1959
Mr. Peter A. ClemensSr. VP, CFO & Sec.220kN/A1953
Dr. Albert W. BrzeczkoVP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc.257kN/A1957
Mr. James F. EmighVP of Corp. Devel.N/AN/A1956
Mr. Robert A. Seiser Ph.D.VP, Treasurer & Corp. ControllerN/AN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.

Corporate Governance

Acura Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.